Opportunity Information: Apply for RFA AI 09 026
Apply for RFA AI 09 026
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jul 31, 2009 and posted on Jul 31, 2009.
- Applicants must submit their applications by Nov 9, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $7,300,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Special district governments Private institutions of higher education For profit organizations other than small businesses Independent school districts Public housing authorities/Indian housing authorities County governments Public and State controlled institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01) funding opportunity (RFA-AI-09-026) is a National Institute of Allergy and Infectious Diseases (NIAID), NIH grant program designed to push promising infectious disease ideas past basic discovery and into practical, translational development. The core goal is to support research projects that directly advance new therapeutic candidates and diagnostic technologies aimed at two especially urgent problem areas: drug-resistant bacteria and eukaryotic parasites. In other words, the program is not simply looking for early-stage biological insights; it is centered on work that can realistically move toward usable products, such as treatments that overcome resistance mechanisms or diagnostics that can detect resistant pathogens or parasitic infections more effectively and guide appropriate care.
This FOA uses the NIH R01 mechanism, which generally supports discrete, hypothesis-driven or milestone-driven research programs led by academic, nonprofit, governmental, or industry investigators. A notable feature is that it is paired with a parallel announcement of the same scientific scope (RFA-AI-09-029) that targets small business applicants through the SBIR R44 mechanism (Phase II and Fast Track). Taken together, the two announcements signal an intent to encourage partnerships and a development mindset, with the R01 route serving organizations that are not applying through SBIR while still emphasizing translational outcomes and product-oriented progress.
NIAID indicated an intent to commit approximately $7.3 million in total costs in fiscal year 2010 for this announcement, with an expected five to ten awards. Funding is competitive and depends on both the availability of appropriated funds and the number of applications judged to be highly meritorious. The FOA also makes clear that award size and duration may vary widely because projects can differ substantially in scope, maturity, and development needs. While the listing includes an award ceiling of $300,000, the broader message is that budgets and timelines should be justified by the proposed translational plan and what is needed to move the technology forward in a credible way.
The opportunity is categorized as discretionary funding and uses the grant funding instrument under the health activity category, tied to CFDA 93.856 (Microbiology and Infectious Diseases Research). There is no cost sharing or matching requirement, which lowers barriers for applicants that may not have substantial non-federal funds available to support the work.
Eligibility is intentionally broad, reflecting the program's emphasis on partnerships and real-world development. Eligible applicants include public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, other than institutions of higher education), for-profit organizations other than small businesses, and small businesses. Government entities at multiple levels are also eligible, including state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The eligibility language further clarifies inclusion of a wide range of institution types and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and other tribal organizations. It also explicitly allows certain non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, faith-based or community-based organizations, and eligible federal agencies, which broadens the pool of potential collaborators and applicants working in regions where resistant bacteria and parasitic diseases may be especially prevalent.
Key dates listed for the announcement show it was posted and created on July 31, 2009, with an original closing date of September 23, 2009, later extended to a current closing date of November 9, 2009, and an archive date of December 9, 2009. The full announcement was made available through the NIH Grants Guide (link provided in the source), and support contacts include the NIH Office of Extramural Research (OER) webmaster addresses for technical issues accessing the materials.
Overall, this FOA is best understood as a targeted NIAID effort to accelerate tangible tools against antimicrobial resistance and parasitic diseases by funding translational research that can credibly move toward a therapeutic or diagnostic endpoint, while encouraging collaboration across academia, industry, nonprofits, and government organizations.
FAQs: Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01) - RFA-AI-09-026
What is this funding opportunity?
This is an NIAID (NIH) funding opportunity titled "Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01)" under FOA number RFA-AI-09-026. It is designed to help move promising infectious disease projects beyond basic discovery and into practical, translational development.
What is the main goal of the program?
The core goal is to support research projects that directly advance new therapeutic candidates and diagnostic technologies for two urgent areas: drug-resistant bacteria and eukaryotic parasites. The emphasis is on credible progress toward usable products, not just early-stage biological insights.
What types of projects does NIAID want to fund under this FOA?
Projects should be translational and product-oriented, such as developing treatments that overcome resistance mechanisms or diagnostics that detect resistant pathogens or parasitic infections more effectively and help guide appropriate care.
Is this opportunity focused on basic science or translational development?
It is centered on translational development. The program is intended to push ideas past basic discovery toward practical therapeutic or diagnostic endpoints.
What grant mechanism is used for this opportunity?
This FOA uses the NIH R01 grant mechanism, which generally supports discrete, hypothesis-driven or milestone-driven research programs.
Is there a related opportunity for small businesses?
Yes. A parallel announcement with the same scientific scope is referenced as RFA-AI-09-029, which targets small business applicants through the SBIR R44 mechanism (Phase II and Fast Track).
What does the existence of both the R01 and SBIR announcements suggest?
Taken together, they signal an intent to encourage partnerships and a development mindset, while providing different application routes depending on whether an applicant is pursuing SBIR or not.
How much funding does NIAID intend to commit, and how many awards are expected?
NIAID indicated an intent to commit approximately $7.3 million in total costs in fiscal year 2010 for this announcement, with an expected five to ten awards.
Is funding guaranteed if an application is submitted?
No. Funding is competitive and depends on both the availability of appropriated funds and how many applications are judged to be highly meritorious.
Is there a specific award ceiling or budget limit?
The listing includes an award ceiling of $300,000. At the same time, the FOA indicates that award size and duration may vary widely depending on project scope, maturity, and development needs, and that budgets and timelines should be justified by the proposed translational plan.
Can award size and project duration vary across funded projects?
Yes. The FOA notes that projects can differ substantially in scope, maturity, and development needs, so award size and duration may vary widely.
What type of funding is this (mandatory vs. discretionary)?
This opportunity is categorized as discretionary funding.
What is the funding instrument?
The opportunity uses the grant funding instrument.
What activity category and CFDA number is associated with this program?
It is under the health activity category and tied to CFDA 93.856 (Microbiology and Infectious Diseases Research).
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (including those with and without 501(c)(3) status, other than institutions of higher education); for-profit organizations other than small businesses; and small businesses.
Are government entities eligible to apply?
Yes. Eligible government entities include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are specific institution types and communities explicitly included?
Yes. The eligibility language explicitly includes HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and other tribal organizations.
Are foreign organizations or non-U.S. entities eligible?
Yes. The eligibility language explicitly allows certain non-U.S. entities (foreign organizations), as well as regional organizations and U.S. territories or possessions.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly included in the eligibility language provided.
Are federal agencies eligible to apply?
Yes. Eligible federal agencies are explicitly mentioned as included.
What are the key dates for this FOA?
The announcement was posted/created on July 31, 2009. The original closing date was September 23, 2009, which was later extended to a current closing date of November 9, 2009. The archive date is December 9, 2009.
Where was the full announcement made available?
The full announcement was made available through the NIH Grants Guide (a link is referenced in the source description).
Who should be contacted for technical issues accessing the announcement materials?
Support contacts include the NIH Office of Extramural Research (OER) webmaster addresses for technical issues accessing the materials.
In plain terms, what is this FOA trying to achieve?
Overall, it is a targeted NIAID effort to accelerate tangible tools against antimicrobial resistance and parasitic diseases by funding translational research that can credibly move toward therapeutic or diagnostic products, while encouraging collaboration across academia, industry, nonprofits, and government organizations.
Browse more opportunities from the same category: Health
Next opportunity: NIMH Career Transition Award for Intramural Investigators (K22)
Previous opportunity: Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (SBIR R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 09 026
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 09 026) also looked into and applied for these:
| Funding Opportunity |
|---|
| CHASS Clinical HIV/AIDS Services Strengthening Mozambique Apply for 674 09 062 Funding Number: 674 09 062 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $135,700,000 |
| HLA Region Genomics in Immune Mediated Diseases (U01, U19) Apply for RFA AI 09 030 Funding Number: RFA AI 09 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for High Throughput Structure Determination (U54) Apply for RFA GM 10 005 Funding Number: RFA GM 10 005 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Straight Talk on Preventing HIV Program Apply for WH HPP 09 006 Funding Number: WH HPP 09 006 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $200,000 |
| 2009 Community Based Surveillance System to Monitor Peri Natal Outcomes within Districts Seven and Eight of Kabul, Afghanistan. Apply for GH GHS 09 002 Funding Number: GH GHS 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $400,000 |
| FY09 Hospital Leadership and Management Capacity Building for Rabia Balkhi Hospital, Kabul, Afghanistan. Apply for GH AWT 09 002 Funding Number: GH AWT 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,000,000 |
| FY09 Youth Empowerment Program (YEP) Apply for MP YEP 09 002 Funding Number: MP YEP 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $300,000 |
| FY09 Health Care Provider Response to Violence Against Women Education, Training and Technical Assistance Program Apply for WH AST 09 001 Funding Number: WH AST 09 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $1,500,000 |
| FY09 Announcement of Availability of Funds for the Emergency System for Advance Registration of Volunteer Health Professionals (ESAR VHP) Program. Apply for EP U3R 09 004 Funding Number: EP U3R 09 004 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $60,000 |
| Part C EIS CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE Apply for HRSA 10 008 Funding Number: HRSA 10 008 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| HIV Prevention Projects Apply for CDC RFA PS10 1001 Funding Number: CDC RFA PS10 1001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Human Immunodeficiency Virus (HIV) Prevention Projects for the Pacific Islands Apply for CDC RFA PS10 1002 Funding Number: CDC RFA PS10 1002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Comprehensive Faith Based HIV/AIDS Prevention, Care and Treatment Apply for RFA 617 09 000003 Funding Number: RFA 617 09 000003 Agency: Uganda USAID Kampala Category: Health Funding Amount: $30,000,000 |
| Initiative to Maximize Research Education in Genomics (R25) Apply for PAR 09 245 Funding Number: PAR 09 245 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Service Area Competitions Additional Areas Apply for HRSA 10 002 Funding Number: HRSA 10 002 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competitions Additional Areas Apply for HRSA 10 003 Funding Number: HRSA 10 003 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| FY09 Hispanic Physicians Leadership Development Initiative Apply for MP MPC 09 012 Funding Number: MP MPC 09 012 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| Immunobiology of Xenotransplantation (U01, U19) Apply for RFA AI 09 035 Funding Number: RFA AI 09 035 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Areas Apply for HRSA 10 158 Funding Number: HRSA 10 158 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (R21) Apply for PA 09 248 Funding Number: PA 09 248 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 09 026", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.